ASKA launches Irinotecan from Actavis in Japan
(Thomson Reuters ONE) -
Tokyo-Zug, 8 February 2012 - ASKA has announced the launch of Irinotecan, the
first oncology product from Actavis in Japan. This product is the anticancer
agent which inhibits the topoisomerase I, and ASKA obtained the marketing
approval on 15 July 2011 and the NHI listing on 28 November 2011.
This product is supplied from the Swiss based pharmaceutical company Actavis
which is marketing the generic products in oncology field globally and is
distributed through Takeda Pharmaceutical Company Limited. Actavis has already
launched Irinotecan in more than 35 countries. Irinotecan Actavis is produced by
the Company's Romanian facility, which is approved by the FDA (US), EMEA (EU)
and the Japanese regulatory authorities.
By launch of this product, ASKA and Actavis will contribute to the restraining
of medical expenses, reducing of patient burden and hospital management. Through
this partnership ASKA and Actavis will make the contribution to the treatment in
oncology area.
Enquiries
Actavis Group
Frank Staud
EVP Corporate Communication
Tel: +41 79 230 95 78
E-mail: fstaud(at)actavis.com
About Actavis Group
Actavis is one of the world's leading generic pharmaceutical companies
specializing in the development, manufacture and sale of generic
pharmaceuticals. The company has operations in more than 40 countries, with
over 10,000 employees. For further information on Actavis Group, please
visitwww.actavis.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actavis via Thomson Reuters ONE
[HUG#1583676]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Oracle Mining appoints Doug Nicholson as Chief Operating OfficerDatum: 08.02.2012 - 11:34 Uhr
Sprache: Deutsch
News-ID 112256
Anzahl Zeichen: 2175
contact information:
Town:
Zug
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 200 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ASKA launches Irinotecan from Actavis in Japan"
steht unter der journalistisch-redaktionellen Verantwortung von
Actavis (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
